Skip to content

Quinic acid attenuates cisplatin-induced acute kidney injury by modulating inflammatory cytokines, oxidative stress, apoptosis, and the Nrf2/HO-1/NQO1 pathway in rats.

Jul 2026 · Immunopharmacology and immunotoxicology · pp. 1-15 · 1 citation · 49 references
Medicine

TL;DR

The antioxidant, anti-inflammatory, anti-apoptotic, and Nrf2-pathway-modulating properties of quinic acid markedly attenuate cisplatin-induced acute kidney injury in rats and its impact on the associated oxidative, inflammatory, apoptotic, and Nrf2/HO-1/NQO1 pathways.

Abstract

Background

The nephrotoxicity induced by cisplatin (Cis) is mediated by oxidative stress, inflammation, and apoptosis, which limit the clinical utility of this commonly used chemotherapeutic drug. Natural polyphenolic compounds such as quinic acid (QA) have cytoprotective and antioxidant properties. This study evaluated the protective effect of QA against cisplatin-induced acute kidney injury (AKI) in rats and its impact on the associated oxidative, inflammatory, apoptotic, and Nrf2/HO-1/NQO1 pathways.

Methods

Forty male Wistar rats were randomly divided into five groups (n = 8): Control, Cis (7.5 mg/kg, i.p.), Cis + QA was administered orally at doses of 25, 50, or 100 mg/kg once daily for 14 days before the cisplatin challenge. Biochemical markers (BUN, creatinine, KIM-1, NGAL), oxidative stress indices (MDA, NO, GSH, TAC, SOD, CAT, GPx), inflammatory cytokines (TNF-α, IL-1β), apoptotic gene expression (Bax, Bcl-2, Caspase-3), and Nrf2 pathway proteins (Nrf2, HO-1, NQO1) were assessed. Renal histopathology was evaluated using blinded scoring.

Results

Cisplatin caused severe renal dysfunction, oxidative imbalance, inflammation, and apoptosis, along with the suppression of Nrf2/HO-1/NQO1 signaling. QA, particularly at doses of 50 and 100 mg/kg, significantly improved serum renal markers, restored antioxidant capacity, reduced MDA and NO levels, downregulated TNF-α and IL-1β, modulated apoptotic gene expression toward cell survival, and enhanced Nrf2-pathway protein levels. Histological injury scores were significantly lower in groups treated with QA.The antioxidant, anti-inflammatory, anti-apoptotic, and Nrf2-pathway-modulating properties of quinic acid markedly attenuate cisplatin-induced AKI. Further mechanistic and translational research on QA to evaluate its potential as a nephroprotective adjunct is warranted.

View source

Similar papers

Aug 2026

Palladium chloride-induced testicular damage in rats: Histopathology, oxidative stress, ER stress, and Nrf2/HO-1 signaling and the protective role of quercetin.

Overall, the findings indicate that Que mitigates PdCl₂-induced testicular injury, and that this protection may be associated with antioxidant, anti-inflammatory, anti-apoptotic, ER stress-related, and Nrf2/HO-1-associated responses rather than direct proof of pathway activation.

Caglar Adiguzel, Hatice Karaboduk, Fatma Gökçe Apaydın et al. · 0 citations
Open access Aug 2026

Nicotinamide Riboside Attenuates Cisplatin-Induced Hepatorenal Toxicity Through Restoration of NAD+ Homeostasis and Nrf2/NQO1-Dependent Antioxidant Signaling

Nicotinamide riboside exerts protective effects against cisplatin-induced hepatorenal toxicity that are mechanistically linked to activation of the Nrf2/NQO1 antioxidant pathway and restoration of hepatic NAD+ homeostasis.

W. Albahadly, M. Rasool, H. Al-Saedi et al. · 0 citations
Open access Jul 2026

Targeting oxidative stress-NLRP3-apoptotic-steroidogenic axis in doxorubicin-induced testicular toxicity: protective efficacy of ferulic acid niosomes

FA-NIO targets oxidative stress-mediated apoptosis, attenuates NLRP3 inflammasome-related signaling, and restores steroidogenic function, thereby successfully attenuating DOX-induced testicular toxicity in rats.

M. M. A. El-Emam, A. Atia, Mona A. Bakry et al. · 0 citations
2026

Hesperidin mitigates DEHP-induced nephrotoxicity through anti-oxidant, anti-apoptotic, and anti-inflammatory pathway modulation: Evidence from Nrf2/HO-1/Keap-1, Bax/Bcl-2/caspase-3, and TLR4/NF-κB axis activation

The protective mechanism involves anti-oxidant enhancement and inhibition of oxidative stress-induced inflammation and apoptosis, supporting the therapeutic potential of HSP in managing phthalate-related renal injury.

Tuba Karaarslan, B. Yıldırım, F. Yildirim et al. · 0 citations
Aug 2026

Morin attenuates vancomycin-induced nephrotoxicity via Nrf-2/HO-1, SIRT1/PGC1α and AKT/FOXO1A pathways

Morin (MOR) treatment significantly ameliorated VCM-induced renal injury by reducing oxidative injury, restoring endogenous defense systems, attenuating inflammatory responses, suppressing apoptosis, and markedly improving histopathological lesions.

S. Tekin, Merve Bolat, Burak Batuhan Laçin et al. · 0 citations
Open access Jul 2026

Targeting Keap1/Nrf2/Ho-1 Pathway May Explain the Ameliorative Effect of Carnosic Acid against Cyclophosphamide-Induced Cardiotoxicity

Cyclophosphamide (Cyclo) is an effective chemotherapeutic agent, but its clinical use is limited by severe cardiotoxicity driven by oxidative stress, inflammation, and apoptosis. Natural antioxidants such as carnosic acid (CA) may offer protection. This study aimed to investigate the protective effects of CA against Cyclo-induced cardiotoxicity in rats and to elucidate the underlying molecular mechanisms. Forty male Wistar rats were divided into four groups: control, CA alone, Cyclo alone, and Cyclo + CA. CA was administered orally at 100 mg/kg for 14 days, while Cyclo was injected intraperitoneally at 100 mg/kg on day 14. Cardiac injury was assessed using serum biomarkers, histology, immunohistochemistry (NF-κB, TNF-α, IL-1β, caspase-3), RT-PCR (Keap-1, Nrf2, HO-1, Bax, Bcl-2), and oxidative stress markers. Cyclo significantly elevated serum cardiac injury markers (CK, troponin, and LDH), as well as hepatic injury markers (ALT and AST), and induced severe histopathological damage, including leukocytic infiltration, congestion, edema, and fibrosis. Mechanistically, Cyclo suppressed the Keap1/Nrf2/HO-1 pathway by downregulating Nrf2 and HO-1 while upregulating Keap-1. Cyclo also depleted antioxidant enzyme activities (SOD, GPx, CAT), increased lipid peroxidation (MDA), activated NF-κB-driven pro-inflammatory cytokines (TNF-α, IL-1β, IL-6), and promoted apoptosis via upregulation of Bax and caspase-3 alongside downregulation of Bcl-2. Co-treatment with CA markedly reversed all these pathological changes, restoring antioxidant and Nrf2/HO-1 signaling, reducing inflammatory markers, inhibiting apoptosis, and improving cardiac histology. CA effectively attenuates Cyclo-induced cardiotoxicity through its antioxidant, anti-inflammatory, and anti-apoptotic properties. These protective effects are likely associated with modulation of the Keap-1/Nrf2/HO-1 and NF-κB signaling pathways, highlighting CA’s therapeutic potential as a natural cardioprotective agent in chemotherapy-associated cardiac injury. Proposed schematic representation of the cardioprotective mechanism of CA against Cyclo-induced cardiotoxicity based on the present findings and previously published literature. Cyclophosphamide exposure leads to cardiac damage through the induction of oxidative stress, inflammation (NF-κB-mediated), and disorganization of cardiac histology, ultimately resulting in cardiotoxicity. Carnosic Acid mitigates this damage by activating the KEAP-1/NRF2/HO-1 pathway. This activation inhibits cytosolic Nrf2 degradation, allowing it to translocate to the nucleus and activate the Antioxidant Response Element (ARE). Concurrently, CA inhibits the NF-κB cascade, reducing the expression of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6). The combined effect is a reduction in oxidative stress (↓ROS, ↓MDA), inflammation, and apoptosis (as indicated by modulated Bax, Bcl-2, and Caspase-3), leading to decreased serum injury markers (CK, LDH, Troponin, AST, ALT, MDA), improved cardiac histology, and mitigation of cardiotoxicity.

Basma Salah, A. Abdelmonsef, Medhat Taha et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.